BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

JCR Pharmaceuticals Achieves Milestone with Alexion in Neurodegenerative Disease Collaboration

-JCR Pharmaceuticals Co., Ltd., a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has achieved ...

September 22, 2025 | News

Mikart and Nano PharmaSolutions Report Positive Phase 1 Data for NT-301 in Parkinson’s Disease

Mikart, LLC, a leading contract development and manufacturing organization (CDMO), and Nano PharmaSolutions, Inc. (NPS), a nanodrug delivery pharmaceutical...

September 19, 2025 | News

BioAge Advances BGE-102 into Phase 1 Trials Triggering Milestone Payment to HitGen as DEL Technology Accelerates Drug Discovery

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technolog...

September 16, 2025 | News

iRegene Secures Over RMB 300 Million in Landmark Series B+ Financing to Advance First-in-Class iPSC Cell Therapies

iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, ...

September 10, 2025 | News

Servier Acquires Kaerus Bioscience’s KER-0193 in Deal Worth Up to $450M

Servier, an independent international pharmaceutical group governed by a foundation, announced that it has entered into a definitive agreement with Kaerus ...

September 09, 2025 | News

Andelyn Biosciences and Tern Therapeutics Partner to Advance Gene Therapy for CLN2 Batten Disease

Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...

September 08, 2025 | News

South Korea’s Neurophet Signs MoU with InRAD to Advance Global Standards for Alzheimer’s and Dementia Data

Neurophet's AI-based brain imaging analysis solutions to support global standardization of Alzheimer's and other dementia-related data Enhancing dementi...

September 03, 2025 | News

Genentech and Alnylam Advance Zilebesiran into Phase III Outcomes Trial for Hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – ...

September 02, 2025 | News

FDA Approves Subcutaneous Leqembi Iqlik, Ushering in a New Era of Alzheimer’s Treatment

U.S. Food and Drug Administration (FDA) announced its approval of a subcutaneous formulation of Leqembi (lecanemab), branded as Leqembi Iql...

September 01, 2025 | News

Actinogen Confirms Commercial Tablet Formulation Of Xanamem Achieves Therapeutic Blood Levels

Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet form...

August 28, 2025 | News

Otsuka Medical Devices Receives Japan Approval For Paradise Ultrasound Renal Denervation System To Treat Resistant Hypertension

Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announced that the Paradise™ Ultrasound Renal Denervation (uRDN) system has r...

August 26, 2025 | News